Dr. Martens (LON:DOCS) Shares Down 12.6% – Here’s What Happened

Dr. Martens plc (LON:DOCS)’s stock price was down 12.6% during mid-day trading on Tuesday . The company traded as low as GBX 65 and last traded at GBX 66.10. Approximately 4,806,140 shares were traded during mid-day trading, an increase of 166% from the average daily volume of 1,808,856 shares. The stock had previously closed at GBX 75.65.

Analyst Ratings Changes

A number of equities analysts recently issued reports on DOCS shares. Peel Hunt reaffirmed a “buy” rating on shares of Dr. Martens in a report on Thursday, November 20th. Berenberg Bank reiterated a “buy” rating on shares of Dr. Martens in a research report on Tuesday. Two analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. According to MarketBeat.com, Dr. Martens presently has a consensus rating of “Moderate Buy” and an average target price of GBX 6,000.

Dr. Martens Stock Performance

The company has a debt-to-equity ratio of 127.27, a quick ratio of 1.13 and a current ratio of 2.85. The stock has a fifty day simple moving average of GBX 75.76 and a two-hundred day simple moving average of GBX 83.16. The stock has a market cap of £657.97 million, a PE ratio of 40.04, a PEG ratio of 6.40 and a beta of 0.11.

Dr. Martens (LON:DOCS) last posted its quarterly earnings results on Thursday, November 20th. The company reported GBX (0.90) EPS for the quarter. Dr. Martens had a return on equity of 18.91% and a net margin of 7.89%. Equities analysts anticipate that Dr. Martens plc will post 2.5809394 EPS for the current fiscal year.

Insider Activity

In other Dr. Martens news, insider Robert Hanson purchased 96,000 shares of the company’s stock in a transaction that occurred on Friday, December 5th. The shares were purchased at an average cost of GBX 79 per share, with a total value of £75,840. Insiders have purchased a total of 97,130 shares of company stock worth $7,673,816 in the last quarter. 2.79% of the stock is owned by insiders.

About Dr. Martens

Founded in 1960, Dr. Martens is an iconic British brand with a global presence. “Docs” or “DMs” were originally
produced for their durability for workers, before being adopted by diverse youth subcultures and associated musical
movements. Today, Dr. Martens has transcended its roots while still celebrating its proud history. It operates in over
60 countries and employs over 3,650 people worldwide. Its operations are split across both Direct-to-Consumer and
wholesale channels, and in addition to its world-renowned “1460” boot its product segments span shoes including the
1461 shoe and Adrian loafer, sandals including the Zebzag mule, Kids ranges, as well as a growing line of bags and
accessories.

The Company successfully listed on the main market of the London Stock Exchange on 29 January 2021 (DOCS.L) and
is a constituent of the FTSE 250 index.